DuneX Biosciences

Executive Summary

DuneX Biosciences is a San Diego-based contract research organization (CRO) founded in 2022, specializing in high-throughput CRISPR functional genomics, yeast display antibody discovery, and non-viral stable cell line development using the Sleeping Beauty transposon system. The company serves biotech and pharmaceutical clients, accelerating antibody and drug discovery workflows, particularly in oncology. While still in its early stages as a private entity with no disclosed funding or revenue, DuneX leverages cutting-edge technologies to provide rapid, scalable, and precise research services. Its position in the growing CRO market and focus on innovative tools like CRISPR screening position it for potential growth, though it faces competition from established players. The lack of public financial data and client disclosures limits visibility, but the company's specialized offerings align with industry trends toward outsourced drug discovery services.

Upcoming Catalysts (preview)

• Q4 2026Announcement of Major Pharmaceutical Partnership40% success
• TBDLaunch of In Vivo CRISPR Screening Service60% success
• 2026Series A Funding Round30% success